| First Author | Farini A | Year | 2022 |
| Journal | Cell Death Dis | Volume | 13 |
| Issue | 11 | Pages | 975 |
| PubMed ID | 36402750 | Mgi Jnum | J:331409 |
| Mgi Id | MGI:7387283 | Doi | 10.1038/s41419-022-05416-1 |
| Citation | Farini A, et al. (2022) Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice. Cell Death Dis 13(11):975 |
| abstractText | Muscle repair in dysferlinopathies is defective. Although macrophage (Mo)-rich infiltrates are prominent in damaged skeletal muscles of patients with dysferlinopathy, the contribution of the immune system to the disease pathology remains to be fully explored. Numbers of both pro-inflammatory M1 Mo and effector T cells are increased in muscle of dysferlin-deficient BlAJ mice. In addition, symptomatic BlAJ mice have increased muscle production of immunoproteasome. In vitro analyses using bone marrow-derived Mo of BlAJ mice show that immunoproteasome inhibition results in C3aR1 and C5aR1 downregulation and upregulation of M2-associated signaling. Administration of immunoproteasome inhibitor ONX-0914 to BlAJ mice rescues muscle function by reducing muscle infiltrates and fibro-adipogenesis. These findings reveal an important role of immunoproteasome in the progression of muscular dystrophy in BlAJ mouse and suggest that inhibition of immunoproteasome may produce therapeutic benefit in dysferlinopathy. |
